Duearity AB (DEAR) - Net Assets
Based on the latest financial reports, Duearity AB (DEAR) has net assets worth Skr-11.54 Million SEK (≈ $-1.24 Million USD) as of June 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr10.84 Million ≈ $1.17 Million USD) and total liabilities (Skr22.38 Million ≈ $2.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Duearity AB total liabilities for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-11.54 Million |
| % of Total Assets | -106.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 138.96 |
Duearity AB - Net Assets Trend (2020–2023)
This chart illustrates how Duearity AB's net assets have evolved over time, based on quarterly financial data. Also explore DEAR total asset value for the complete picture of this company's asset base.
Annual Net Assets for Duearity AB (2020–2023)
The table below shows the annual net assets of Duearity AB from 2020 to 2023. For live valuation and market cap data, see Duearity AB stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | Skr-2.39 Million ≈ $-256.77K |
-139.35% |
| 2022-12-31 | Skr6.06 Million ≈ $652.48K |
-45.08% |
| 2021-12-31 | Skr11.04 Million ≈ $1.19 Million |
+191.03% |
| 2020-12-31 | Skr3.79 Million ≈ $408.19K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Duearity AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6041900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr1.27 Million | % |
| Other Comprehensive Income | Skr282.00K | % |
| Other Components | Skr57.80 Million | % |
| Total Equity | Skr-2.39 Million | 100.00% |
Duearity AB Competitors by Market Cap
The table below lists competitors of Duearity AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Cardiff Property PLC
LSE:CDFF
|
$331.99K |
|
LeddarTech Holdings Inc
NASDAQ:LDTC
|
$334.76K |
|
Glob Bioenergi
PA:ALGBE
|
$335.38K |
|
PBT Group Ltd
JSE:PBG
|
$335.60K |
|
Subsea 7 SA
LSE:0OGK
|
$331.83K |
|
Carclo plc
LSE:CAR
|
$331.41K |
|
Challenger Energy Group PLC
LSE:CEG
|
$331.01K |
|
Rajvir Industries Limited
NSE:RAJVIR
|
$330.50K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Duearity AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 6,063,000 to -2,386,000, a change of -8,449,000 (-139.4%).
- Net loss of 26,190,000 reduced equity.
- New share issuances of 618,000 increased equity.
- Other comprehensive income increased equity by 282,000.
- Other factors increased equity by 16,841,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-26.19 Million | -1097.65% |
| Share Issuances | Skr618.00K | +25.9% |
| Other Comprehensive Income | Skr282.00K | +11.82% |
| Other Changes | Skr16.84 Million | +705.83% |
| Total Change | Skr- | -139.35% |
Book Value vs Market Value Analysis
This analysis compares Duearity AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | Skr0.27 | Skr0.02 | x |
| 2021-12-31 | Skr0.93 | Skr0.02 | x |
| 2022-12-31 | Skr0.40 | Skr0.02 | x |
| 2023-12-31 | Skr-0.13 | Skr0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Duearity AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1583.43%
- • Asset Turnover: 0.11x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-123.52%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -34.93% | -212339.74% | 0.00x | 1.15x | Skr-1.70 Million |
| 2021 | -140.58% | -8894.15% | 0.01x | 1.46x | Skr-16.62 Million |
| 2022 | -318.56% | -3229.77% | 0.05x | 1.99x | Skr-19.92 Million |
| 2023 | 0.00% | -1583.43% | 0.11x | 0.00x | Skr-25.95 Million |
Industry Comparison
This section compares Duearity AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $190,895,586
- Average return on equity (ROE) among peers: -31.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Duearity AB (DEAR) | Skr-11.54 Million | -34.93% | N/A | $331.97K |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $33.84 Million |
| Arcoma AB (ARCOMA) | $48.66 Million | 5.27% | 0.68x | $11.55 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $61.64 Million |
| BICO Group AB (BICO) | $2.31 Million | 0.00% | 2.47x | $159.82 Million |
| Boule Diagnostics AB (BOUL) | $295.74 Million | 7.87% | 0.93x | $14.38 Million |
| CellaVision AB (CEVI) | $887.58 Million | 17.25% | 0.23x | $311.10 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $26.09 Million | -70.24% | 0.12x | $11.57 Million |
| Chordate Medical Holding AB (CMH) | $25.64 Million | -77.06% | 0.22x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $29.82 Million | -34.38% | 0.50x | $86.08 Million |
About Duearity AB
Duearity AB (publ), a medical technology company, engages in the development and production of solutions for tinnitus. The company offers Tinearity G1, a medical device for people suffering from tinnitus that transmits white noise using bone conduction technology non-invasively to the inner ear in order to treat and relieve symptoms; and Tinearity-AI, which uses artificial intelligence to help pe… Read more